Fig. 1
From: Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells
Mutp53 promotes cell proliferation. a Western blot analysis of p53 and p21 levels in mouse ErbB2 mammary epithelial tumor cell lines with different p53 status. Actin is loading control. b Growth curve of mouse ErbB2 mammary epithelial tumor cell lines with different p53 status. n = 3 independent experiments per genotype (one cell line per genotype except for p53+/+ and p53 H/− where 2 different cell lines derived from different tumors and result per genotype was averaged). c Bar graph showing percent mitotic cells in mouse ErbB2 mammary epithelial tumor cell lines with different p53 status. Each bar represents the average percent of mitotic per genotype counted from at least 5 randomly selected fields at × 400 magnification (one cell line per genotype except for p53+/+ and p53 H/− where 2 different cell lines derived from different tumors and result per genotype was averaged). d Bar graph showing relative mRNA expression level of p21 in ErbB2 mammary epithelial tumor cell lines with different p53 status. n = 3 independent experiments per cell line per genotype. e Western blot analysis of p53 and p21 levels in mouse ErbB2 mammary epithelial tumor cell lines with different p53 status before and after CRISPR/Cas9 p53 deletion (p53CC9). Hsc70 is loading control. f Growth curve of mouse ErbB2 mammary epithelial tumor cell line with mutp53, before and after CRISPR/Cas9 p53 deletion (p53CC9). n = 3 independent experiments per cell line. Where applicable *p < 0.05; **p < 0.01; ***p < 0.001. Error bars represent ± SD